

Robert Kamen Joins Numab's Advisory Board

Wädenswil, Switzerland, July 30, 2013 – Numab AG, a Swiss biotech company, today announces the appointment of Dr. Robert Kamen to Numab's Advisory Board. Dr. Kamen has more than 30 years of experience in the pharmaceutical and biotechnology industry. As president of Abbott Bioresearch Center (formerly BASF Bioresearch Corporation) Dr. Kamen was responsible for the discovery and production of anti-TNF α antibody Humira® currently being the best-selling drug of the world. Previously, Dr. Kamen led discovery at Genetics Institute, Inc. Dr. Kamen is furthermore a co-founder of BioAssets Development Corporation that was acquired by Cephalon in 2010. He currently serves as interim chief technology officer of Jounce Therapeutics and entrepreneur-in-residence of Third Rock Ventures. In addition, Dr. Kamen is a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics, and advises other biopharmaceutical companies.

Robert Kamen commented his decision to join Numab's advisory board: "Numab's approach to antibody discovery is to exhaustively characterize the antibody repertoire of immunized rabbits. Together with their robust technology to engineer drug-like bi-specific antibody-based molecules, I believe that the company is very well positioned to make an impact on the next generation of antibody-based therapeutics, as exemplified by Numab's bi-specific anti-CD3/anti-IL23R program." Oliver Middendorp, CBO, co-CEO and co-founder of Numab, added: "We are very proud to have Bob Kamen on our Advisory Board. His huge experience and credibility in the field of therapeutic antibodies will be of great help to further advance Numab's recognition as a leader in the field".

About Numab AG:

Numab is a privately-owned Swiss biotech company located in Wädenswil, Zurich. The Company discovers and develops innovative antibody-based therapeutics to fuel its proprietary pipeline, as well as the pipelines of its partners in the pharmaceutical industry. Numab's lead program ND007 is being developed for the treatment of chronic inflammatory disorders such as rheumatoid arthritis, psoriasis or multiple sclerosis. ND007 carries the promise of being superior over existing therapies in terms effect size, effect duration and safety. Numab applies proprietary antibody discovery and engineering technology to reproducibly generate highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or bi-specific antibody fragment-based therapeutics with tailored pharmacokinetic properties.

For further information please contact:

Oliver Middendorp
o.middendorp@numab.com

or visit:

www.numab.com